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Abstract
Background: A tenth of all people who inject drugs in Kenya are women, yet their social contexts and experiences
remain poorly understood. This paper reports how multiple forms of stigma are experienced by women who inject
drugs in coastal Kenya and the impact that they have on their ability to access essential health services.
Methods: In 2015, in-depth interviews and focus group discussions were held with 45 women who inject drugs in
two coastal towns. These data were supplemented with in-depth interviews with five individual stakeholders
involved in service provision to this population. Data were analyzed thematically using NVivo.
Results: Women who inject drugs experience multiple stigmas, often simultaneously. These included the external
stigma and self-stigma of injection drug use, external gender-related stigma of being a female injecting drug user,
and the external stigma of being HIV positive (i.e., among those living with HIV). Stigma led to rejection, social
exclusion, low self-esteem, and delay or denial of services at health facilities.
Conclusion: HIV and harm reduction programs should incorporate interventions that address different forms of
stigma among women who inject drugs in coastal Kenya. Addressing stigma will require a combination of
individual, social, and structural interventions, such as collective empowerment of injecting drug users, training of
healthcare providers on issues and needs of women who inject drugs, peer accompaniment to health facilities,
addressing wider social determinants of stigma and discrimination, and expansion of harm reduction interventions
to change perceptions of communities towards women who inject drugs.
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Background
Injecting drug use is a significant driver of the global HIV
epidemic [1]. In Kenya, 18.7% of people who inject drugs
are HIV positive [2], which is three times the national
prevalence of 5.6% [3]. In this context, gender vulnerabil-
ities influence HIV acquisition. HIV prevalence is higher
among women than men, both in the general population
and among people who inject drugs [4, 5]. In addition, a
marked geographic variation in HIV prevalence exists.
Among injecting drug users, HIV prevalence is higher at
the coast [2, 6].
To reduce social and health harms related to injecting
drug use, a comprehensive package of harm reduction
interventions is recommended for all persons who inject
drugs. This package includes needle and syringe ex-
change programs (NSPs), opioid substitution therapy
with methadone (OST), and prevention and treatment
of a range of infectious diseases including HIV, viral
hepatitis, tuberculosis, and sexually transmitted infec-
tions [7].
Despite the known benefits of harm reduction services
for persons who inject drugs [8], provision of these
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interventions remains sub-optimal globally [9, 10]. In
Kenya, the Ministry of Health endorsed the harm reduc-
tion approach in 2013 [11] and, in 2014, introduced NSP
and OST in selected government facilities [12]. However,
less than a fifth of an estimated 18,327 people who inject
drugs in Kenya are being reached by the national NSP
[3], access to OST with methadone is limited [13], and
needle/syringe sharing is common [6].
In this context, drug use is generally stigmatized, and
several authors have suggested that access to services
could be restricted by the social perception of injecting
drug use. Stigma is defined as the co-occurrence of la-
beling, stereotyping, separation, and discrimination in
response to a discrediting attribute that is associated
with loss of status [14, 15]. Through social and structural
mechanisms, stigma reinforces existing inequalities and
power imbalances such as those due to gender, ethnicity,
physical characteristics, and so forth [16]. Enactments of
stigma manifest as overt discrimination [14, 17], which
may restrict stigmatized individuals’ access to important
health services [18, 19].
Women who inject drugs often face gender and power
inequalities [20]. In Kenya, women comprise of a tenth
of all injecting drug users [21], yet they have received
very limited attention to date [22]. There is limited un-
derstanding of these women's social contexts in Kenya,
partly because injecting drug use has been relatively rare
in sub-Saharan Africa compared to other global regions
[23, 24]. Given the rising prevalence of injecting drug
use in Kenya [23], we sought to unpack their lived expe-
riences, explore how stigma could affect their access to
health services, and recommend corrective actions.
We conducted a qualitative study whose aim, broadly,
was to explore the needs and social contexts of women
who inject drugs in coastal Kenya. We report ways in
which women who inject drugs experience stigma and
discrimination and the impacts that stigma and discrim-
ination may have on their abilities to access health ser-
vices. We propose potential programmatic and policy
approaches that can mitigate the impact of stigma on
service access.
Methods
Study design
In 2015, a combination of in-depth interviews and focus
group discussions (FGDs) was conducted among women
who inject drugs. These were complemented with
in-depth interviews conducted with selected key infor-
mants involved in providing harm reduction services to
this population.
Setting
Data were collected from women who were accessing
community-based harm reduction services in Mombasa
and Kilifi. These services were being provided to injecting
drug users through a partnership of three
community-based organizations (CBOs): Kenya AIDS
NGOs Consortium (KANCO), Reach out Centre Trust
(REACH OUT), and the Muslim Education and Welfare
Association (MEWA). Through outreach and linked
drop-in services operated by these CBOs, injecting drug
users were provided with clean needles, syringes, addic-
tion counseling, HIV counseling and testing, condoms,
pregnancy tests, and oral contraceptives. Clients who re-
quired additional services were referred to surrounding
private and government facilities.
Participant selection and recruitment
Participants included 45 women who inject drugs and
five key stakeholders. Of the 45 women, 24 participated
in in-depth interviews (12 at each site) and 21 partici-
pated in three focus group sessions (three sessions in
Mombasa and one session in Kilifi). To be included, par-
ticipants had to be older than 18 years of age, so that
they could provide independent consent; be within the
reproductive age bracket of 18–49 years; and have a his-
tory of injecting drugs within the 90 days preceding the
study. Women were invited to participate in the study
by outreach workers during the course of their routine
outreach, and those who accepted the invitations based
on availability were screened and scheduled for appoint-
ments. In consultation with representatives from the two
CBOs, five key stakeholders were purposively sampled
based on their roles, expertise, and political or commu-
nity representation. The selected stakeholders included
one community health worker, two outreach workers,
one ministry of health official, and one outreach
manager.
Data collection
In-depth interviews and FGDs were conducted in pri-
vate rooms at the CBOs or at key stakeholders’ offices
by two experienced interviewers (SA and JN). In-depth
interviews and FGDs explored drug use, sexual and
reproductive health, HIV testing experiences, and
access to outreach or conventional government health
services. All in-depth interviews and FGDs were con-
ducted in Swahili or English, based on participants’
preferences, were audio recorded, and lasted between
45 and 60 min. At the end of in-depth interviews and
FGDs, basic socio-demographic data were collected
from participants.
Data analysis
A summary of socio-demographic data was generated
using Microsoft Excel (Microsoft Corporation, Redmond,
Washington). Interviews and FGDs were transcribed into
English, and thematic analysis conducted [25]. Transcripts
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were imported into NVivo® [26], and codes were gener-
ated independently by GM and JN. Recurrent themes
were identified while examining the data for nuances,
similarities, and differences through constant comparison
approach [27]. Final codes were categorized to generate
themes related to women’s experiences of stigma and its
impact on their access to health services.
Ethical considerations
This research was conducted in accordance with the
World Medical Association’s [28] provisions governing
research with human subjects. Data were collected in
private rooms, written informed consent was obtained,
and participants retained the right to withdraw partici-
pation at any time. Unique codes were used to track par-
ticipants in lieu of names or other identifying
information, and the data were password-protected. Eth-
ical approval was provided by the National Commission
for Science Technology and Innovation (ref: P/15/8861/
4510).
Results
Participant characteristics
The mean age of the 45 women was 28.5 years. Majority
were single, with at least one child, without secondary
education, and either unemployed or working in infor-
mal sector. On average, participants had used polydrugs
for a period of 8.5 years, and had specifically injected
drugs for 2.6 years. Overall, 29% were sex workers, and
over two thirds (69%) were not using contraception. The
main drug injected was heroin (Table 1).
Typologies and multiplicity of stigma
Our study found several forms of stigma. These were the
stigmas of being a drug user, gender-related stigma of
being a female injecting drug user, and the stigma of be-
ing HIV positive (i.e., among those living with HIV).
Self-stigma of women who inject drugs
Participants’ accounts indicated a self-directed shameful
consciousness of being an injecting drug user. Internal-
ization of stigma was often associated with low
self-esteem. Indeed, some participants constructed these
self-stigmatized identities in such a way as to make it
impossible to have meaningful relationships, believing
that they were not worth being loved:
You can meet someone who pretends to love and
[desire] you. Who has ever loved a drug addict? It’s a
lie. (Participant 10 Mombasa).
Self-stigmatization resulted from study participants in-
ternalizing the negative perceptions of injecting drug use
within the study setting, where drug use was generally
construed as resulting from a failure of individual moral-
ity. Injecting drug users were commonly referred as
“teja” to which translates into “an injecting drug user” or
“client” in a demeaning way. Not surprisingly, among
the participants, the identity of being a drug user or
“teja” was seen as shameful and regrettable. Hence, these
stigmatized participants had an interest in concealing
their stigmatized identities:
I usually don’t like people to know [that I inject
drugs] because I feel shame. (Participant 12, Kilifi).
Table 1 Participant characteristics
Characteristic IDIs FGDs Total Percent
Age (mean, years) 26.4 30.5 28.4 –
Number of children (mean) 1.6 –
Education
None 4 4 8 18
Primary 13 10 23 51
Secondary 6 6 12 27
Post-secondary 0 1 1 2
Unknown 1 0 1 2
Marital status
Married 5 3 8 18
Live in partner 7 5 12 27
Single 11 13 24 53
Unknown 1 0 1 2
Income source
Casual labor 2 5 7 16
Food Kiosk/plaiting 3 2 5 11
Sex work 9 4 13 29
Peddling 1 2 3 7
Peer educator 0 1 1 2
Family or partner 3 1 4 9
Begging, hustling 5 6 11 24
Unknown 1 0 1 2
Contraception
Yes 11 3 14 31
No 13 18 31 69
Drug use
Duration using drugs (years) 7.8 9.1 8.5 –
Duration injecting (years) 3.3 2.0 2.6 –
Main drugs used
Heroin 11 1 12 27
Heroin and other drugs* 11 15 26 58
Cocaine 1 3 4 9
Cocaine and other drugs* 1 2 3 6
*Varied combination of substances including Rhohypnol, khat, cigarettes,
and alcohol
Mburu et al. Harm Reduction Journal  (2018) 15:29 Page 3 of 8
External stigmatization of injecting drug use in
communities and health facilities
Although women experienced different degrees of
stigmatization, they consistently perceived negative atti-
tudes towards injecting drug use from their communities:
You know when you start using illicit drugs, obviously
people who do not use will refuse to associate with
you. No one will accept to walk with you when you
are a drug addict. You will have to associate with your
fellow drug users. (Participant 7, Mombasa).
Others stated that they were also stigmatized by their
own family members:
From my own perspective, even the outreach workers
are more concerned with us and love us even more
than our families. The family contributes to our
suffering as they say: “you are a drug addict; you are
as good as dead”. If you try explaining anything to
them, they see you as nothing but a drug addict. It
pains. (Participant 10, Mombasa).
Participants described how this stigma was operation-
alized within a milieu of social dynamics and moralistic
attitudes, conveying a notion of moral judgment:
They think a teja [drug user] is as bad person.
(Participant 10, Mombasa).
This stigmatization was linked to moralistic judge-
ments and suspicion, as drug users were generally
viewed as likely to be petty criminals:
You can have a friend, maybe a neighbor, but if s/he
knows, s/he will think: “so this one is an injecting
drug user, aah it is over! Either thieves will steal from
me or she will influence my children to snort or
smoke [drugs]” Most of them in Mombasa are fond of
that. (Participant 10, Mombasa).
Participants’ accounts suggested that although drug
use was generally stigmatized, this stigma was accentu-
ated among women. Accounts suggested that women
perceived a unique stigma of drug use, because injecting
drug use ran contrary to gendered norms of behavior.
One stakeholder illustrated the prevalent negative per-
ception of injection drug use by women, claiming that
“it is a shame for a woman to be an injecting drug user”
(Stakeholder 3, Kilifi).
Apart from experiencing it in communities, the stigma
of injecting drug use was frequently experienced in
healthcare settings. Asked about her experience with
health care providers, one participant reported that “they
despise us a lot” (Participant 10, Kilifi). Another com-
mented that “they tell each other: ‘that is a drug user’”
(Participant 5, Kilifi).
Stigma of being an HIV positive drug user
Our data provided insight into the cognitive and emo-
tional experiences when the stigma of being a female
drug user was layered over HIV-related stigma. Our data
suggested that both can exist simultaneously. Partici-
pants who were HIV positive described perceiving HIV
stigma, even from their fellow drug users, suggesting
that their experiences as women who inject drugs and
who lived with HIV were different from the experiences
of women who inject drugs who were not HIV positive:
Now a fellow drug user tells you “Get out of here,
didn’t we go with you to REACHOUT and got tested,
and it was found that you are HIV positive?”
(Participant 3, Mombasa).
These claims were confirmed by HIV negative partici-
pants, who constantly viewed HIV with stigmatizing sus-
picion. Their accounts suggested that being HIV positive
was a different source of shame among women who
injected drugs. In an illustrative comment, one partici-
pant suggested that she was very careful not to acquire
HIV as “there is nothing [as] shameful as HIV” (Partici-
pant 12, Mombasa). As can be noted from this extract,
her concerns were not necessarily related to the health
effects of HIV infection but rather to the social percep-
tion of being HIV positive.
Negative impact of stigma
Regardless of its source, stigmatization of women
seemed to result in isolation and exclusion through pre-
judiced social processes and institutional practices.
Responding to a question about the impact of stigma,
one woman described how families and associates “aban-
don you and run away” (FGD 2, Mombasa) once she
began injecting drugs. Referring to social distancing and
its reasons, another opined that “people cannot agree to
be with someone who is snorting or injecting drugs”
(Participant 9, Kilifi). This distancing was also exempli-
fied in the experiences of another participant, who
asserted that her “best friend doesn’t use” and as a result
their “friendship has reduced” (Participant 11, Kilifi).
Apart from social isolation, our data suggested that
enactments of stigma—overt discrimination—served as a
significant barrier to health service access. Participants
characterized the actions of health providers as “scornful
maltreatment” (Participant 10, Mombasa). Discrimin-
ation was common, whereby drug users were isolated
and served last within health facilities:
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Should they know that you are an addict, they send
you backwards on the queue or tell you to go and
come later. (Participant 10, Kilifi).
Participants’ narratives suggested that they were con-
cerned about being identified or recognized as drug
users within facilities, as this inevitably affected the qual-
ity of their interactions with health care providers, and
ultimately delayed their services:
You get in the queue and you are the last one to be
served, or they take you round from one place to the
other once they know you are a drug user.
(Participant 5, Kilifi).
Apart from existing negative perceptions of drug use,
stakeholders suggested that “the health care workers did
not understand why and how they needed to serve fe-
male drug users” (Stakeholder 3, Kilifi). Nevertheless,
given women’s experiences, some of them opted not to
seek health services. For one participant, being stigma-
tized at health facilities meant that she had “never gone
back” (Participant 10, Kilifi). Yet, many women inevit-
ably found themselves compelled by circumstances to
seek health services, and in those situations, they strived
to conceal their identities, so as to avoid being stigma-
tized or discriminated against:
I was forced to tell the truth that I was an addict. It
was by luck that I met a good nurse. Had I have
found the wrong one, I would have been insulted a
lot, and not attended to. (Participant 10, Mombasa).
In many cases, participants opted to be accompanied
by outreach workers in their visits to health facilities, so
as to mitigate the effects of stigma. One participant
asserted that “if you come along with an outreach
worker, the health providers give you the required ser-
vices but if you come alone, they may not attend to you”
(Participant 10, Mombasa). Other participants suggested
that the mediating role of CBOs extended to referral
slips which were provided by outreach services:
Immediately they see this [referral] paper from
REACHOUT they treat you with respect. If you don’t
have one, you can be really mistreated, you can get
there at 7 am and leave at even 5 pm, 8 pm or even
10 pm. (Participant 12, Mombasa).
Discussion
In this qualitative study of 45 women who inject drugs and
five stakeholders who were involved in the provision of
harm reduction services, we report various experiences of
stigma and discrimination among women who inject drugs
in coastal Kenya. Specifically, this study found that several
forms of external and self-stigma are concurrently experi-
enced by these women. These include internal and external
stigma of being a drug user, external gender-related stigma
of being a female injecting drug user, and external stigma
of being HIV positive among participants who were living
with HIV.
The finding of self-stigma is consistent with other
studies which have described internalized self-stigma
among persons who inject drugs, which in turn leads to
feelings of shame, low self-esteem, and reduced
self-efficacy [29, 30]. In terms of external stigmatization
within social and healthcare settings, other studies from
India, Mexico, Vietnam, and the UK have also shown
that women who inject drugs frequently experience se-
vere stigma and social exclusion from their communities
due to social disapproval of female injecting drug use
[31–34]. Similar to these studies, our findings suggest
that gendered norms of behavior operated in conjunc-
tion with stigma of drug use to exacerbate stigma faced
by women who injected drugs.
On their part, HIV positive women who injected drugs
experienced a simultaneous layering of multiple stigmas.
In addition to experiencing stigma related to injecting
drug use, HIV positive women perceived HIV-related
stigma. HIV negative injecting drug users in our study also
stigmatized their HIV positive colleagues, demonstrating
that injecting drug users were themselves liable of stigma-
tizing others. In the UK, injecting drug users tended to
stigmatize other injecting drug users they believed to be
worse than them—primarily the homeless [35].
Our study shows that different forms of stigmatization of
women who inject drugs are a potent barrier to their access
and utilization of health services. Experiencing shame asso-
ciated with one’s drug use can lead to avoidance of harm
reduction [35] and general healthcare services [36]. In our
study, poor access to services was mediated by poor inter-
actions with, or overt discrimination by health providers.
Other studies have shown that stigma is often a driver of
problematic patient-provider relationships [37], which act
in concert with isolation [38], and other healthcare barriers
to limit drug users’ utilization of health services. Although
this was not apparent in our study, layering of internalized
stigma and HIV-related stigma also act simultaneously to
prevent engagement of injecting drug users with HIV care
in other settings [18]. These findings suggest that unless the
stigma confronting women who inject drugs is mitigated,
the health of this marginalized population is likely to get
worse.
Implications
Addressing different forms of stigma will be essential to
mitigate their negative impacts on women’s ability to
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access health services. These can be addressed at indi-
vidual, social, and structural levels. At the individual
level, interventions that support reversal of internalized
stigma are required. Unfortunately, few interventions for
effectively combating internalized stigma exist [39].
However, research among stigmatized populations has
shown that collectivization and peer-based support ap-
proaches can assist in coping and confronting self and
external stigma, by harnessing collective self-efficacy,
and providing an environment to transform self-esteem
[40, 41]. As such, increasing recruitment of female
peers and forming peer support groups of women who
inject drugs would be critical to overcoming self-stigma
in the study context. It can also strengthen women’s
negotiating power to access social and health entitle-
ments, as has been the case among other stigmatized
populations [42].
At the social level, addressing moralistic judgements
and attitudes that reinforce conservative, but often in-
equitable stigmatization of women who inject drugs will
be essential. Working with community and religious
leaders as an avenue to tackle stigma at the coast might
be useful. Resistance from the local county government
and community members might be encountered, given
the prevalent social perception of drug use in coastal
Kenya. However, community-based advocacy and out-
reach to religious and other community leaders has been
shown to soften hard community stances and to reduce
community discrimination against drug users in
Vietnam [43]. The success of such an approach would
be in combining education to communities about the
possible harmful effects of adhering to prevalent stigma-
tizing attitudes towards women who inject drugs, while
informing them of the benefits of harm reduction in in-
creasing social functioning and health of injecting drug
users. Thus, the local leadership needs to see drug use
as partly a symptom of social problems that confront
women, rather than an issue of simple individual choice
that abstinence and prohibition can solve. Because com-
munity support and commitment is essential in combat-
ing social stigma against drug users [43, 44],
community-based programs (for example through
CBOs) that can reach communities with anti-stigma
messages will need to be geographically expanded, polit-
ically supported, and financially resourced.
At the structural level, interventions to eliminate
stigmatization in healthcare settings will be crucial. The
need to train healthcare providers on issues and needs
of injecting drug users in the Kenyan coast has already
been noted, given the rising number of women who in-
ject drugs, who will require health services [22]. Involve-
ment of women in training and service delivery could be
particularly useful as it has been shown to facilitate un-
derstanding of their needs and a change of negative
attitudes among healthcare providers in Tanzania [45].
Providing health workers with a broader understanding
of injecting risk behaviors has also been a critical part of
responses to injecting drug use in the USA, Thailand,
and other countries with established harm reduction
programs [46, 47]. For optimal impact, the expanded
training will need to be accompanied by an increased
provision of the globally recommended comprehensive
package of harm reduction services [7]. On their part,
healthcare staff must resist the reproduction of stigma in
health care settings and should learn and use drug user’s
language in interactions with them. Creating opportun-
ities for multiple encounters and making a personal con-
nection have been shown to generate trust between drug
users and health providers in Tanzania [45], and such an
approach could allow health providers in our study's
context to be familiar with, and change their attitudes
towards injecting drug users. In addition, our study sug-
gests that peer accompaniment and support to navigate
health facilities should be continued as a strategy to me-
diate communication with health providers and reduce
experiences of stigma among women who inject drugs.
In future, online stigma reduction training of health pro-
viders using hypothetical scenarios and concerns around
injecting drug users, which was found to have a positive
impact on stigmatizing attitudes among Australian
health providers [48], could be adapted for our study’s
context.
However, addressing the social and health systems
drivers of stigma need to be linked to wider social deter-
minants of stigma and discrimination. Redirecting gov-
ernment drug policy from being exclusively abut clinical
treatment to also include community and socially ori-
ented harm reduction interventions will be crucial in
mitigating stigma, as it provides an avenue to strengthen
employment [49], livelihoods and skills development
[22], progressive policing [50], legal support, and
violence mitigation within a rights-based approach [20,
43, 51]. These interventions, combined with widespread
expansion of services to all drug users, will likely trigger
a change in social attitudes towards women who inject
drugs.
Limitations
Several limitations of our findings should be noted. Our
study involved participants who were in contact with
community-based harm reduction services, whose ac-
counts and experiences of stigma may differ from other
women. It is indeed possible that our study may be
underestimating the impact of stigma among women
who inject drugs in Kenya, because our samples were
already accessing pyschosocial and other harm reduction
services. Our study did not include clinical service pro-
viders, who might have provided useful triangulating
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information regarding their attitudes towards women
who inject drugs. Nevertheless, this study contributes to
the knowledge base regarding the social contexts of
women who inject drugs in Kenya, upon which tailored
interventions can be based, and future studies be built
upon.
Conclusions
Without purporting to fully understand or to oversim-
plify the contexts and experiences of stigma, it is clear
that women who inject drugs in the Kenyan coast often
self-stigmatize, face stigma of injecting drug use in social
contexts and health care facilities, and are discriminated
by healthcare providers, which deters their access and
utilization of health services particularly harm reduction,
HIV and reproductive health services. In addition, these
stigmas are overlaid on HIV-related stigma among
women who are living with HIV. To overcome the mul-
tiple forms of stigma simultaneously experienced by par-
ticipants in this study and ensure that tailored
gender-sensitive interventions are available to them, a
range of specific individual-, social-, and structural-level
interventions will need to be implemented.
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